HK1160766A1 - Combination of aurora kinase inhibitors and anti-cd20 antibodies cd20 - Google Patents

Combination of aurora kinase inhibitors and anti-cd20 antibodies cd20

Info

Publication number
HK1160766A1
HK1160766A1 HK12101147.6A HK12101147A HK1160766A1 HK 1160766 A1 HK1160766 A1 HK 1160766A1 HK 12101147 A HK12101147 A HK 12101147A HK 1160766 A1 HK1160766 A1 HK 1160766A1
Authority
HK
Hong Kong
Prior art keywords
antibodies
combination
kinase inhibitors
aurora kinase
aurora
Prior art date
Application number
HK12101147.6A
Other languages
English (en)
Chinese (zh)
Inventor
馬克‧曼弗雷迪
Original Assignee
米倫紐姆醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 米倫紐姆醫藥公司 filed Critical 米倫紐姆醫藥公司
Publication of HK1160766A1 publication Critical patent/HK1160766A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK12101147.6A 2008-12-22 2012-02-07 Combination of aurora kinase inhibitors and anti-cd20 antibodies cd20 HK1160766A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20350908P 2008-12-22 2008-12-22
PCT/US2009/006560 WO2010074724A1 (en) 2008-12-22 2009-12-15 Combination of aurora kinase inhibitors and anti-cd20 antibodies

Publications (1)

Publication Number Publication Date
HK1160766A1 true HK1160766A1 (en) 2012-08-17

Family

ID=41664630

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12101147.6A HK1160766A1 (en) 2008-12-22 2012-02-07 Combination of aurora kinase inhibitors and anti-cd20 antibodies cd20

Country Status (13)

Country Link
US (3) US20100183601A1 (xx)
EP (1) EP2376082B1 (xx)
JP (1) JP5738196B2 (xx)
KR (1) KR101741168B1 (xx)
CN (1) CN102264368B (xx)
AU (1) AU2009330727B2 (xx)
BR (1) BRPI0923579A2 (xx)
CA (1) CA2747326C (xx)
ES (1) ES2468391T3 (xx)
HK (1) HK1160766A1 (xx)
MX (1) MX2011006725A (xx)
RU (1) RU2535032C2 (xx)
WO (1) WO2010074724A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006725A (es) 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
RU2012140021A (ru) 2010-02-19 2014-03-27 Миллениум Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ
US9724354B2 (en) * 2013-03-22 2017-08-08 Millennium Pharmaceuticals, Inc. Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase
EP3076963A4 (en) * 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
EP3551046B1 (en) 2016-12-07 2023-07-19 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
KR20210095165A (ko) 2018-11-19 2021-07-30 프로제너티, 인크. 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스
CN115666704A (zh) 2019-12-13 2023-01-31 比奥拉治疗股份有限公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
NL8000715A (nl) 1979-02-07 1980-08-11 Hoffmann La Roche Pyrimido-2-benzazepinen, werkwijzen ter bereiding ervan, alsmede farmaceutische preparaten, die deze pyrimido-2- benzazepinen bevatten.
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
US6124281A (en) 1996-03-08 2000-09-26 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
TW510902B (en) 1997-09-29 2002-11-21 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
EP1207906A4 (en) * 1999-08-11 2005-07-06 Biogen Idec Inc TREATMENT OF NON-HODGKIN LYMPHOMA PATIENTS WITH BONE MARROW WITH INVOLVEMENT OF ANTI-CD20 ANTIBODIES
CA2390412A1 (en) * 1999-11-08 2001-05-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy
AU2001227851A1 (en) * 2000-01-12 2001-07-24 Emag Technologies L.L.C. Low cost compact omni-directional printed antenna
JP2003531178A (ja) * 2000-04-25 2003-10-21 アイデック ファーマスーティカルズ コーポレイション 中枢神経系リンパ腫治療用のリツキシマブのクモ膜下投与
ATE326462T1 (de) 2000-12-21 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinase- inhibitoren
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
WO2003013545A1 (en) 2001-08-09 2003-02-20 Actelion Pharmaceuticals Ltd Novel benzo-fused heterocycles as endothelin antagonisits
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
SI1847539T1 (sl) 2002-12-24 2010-01-29 Astrazeneca Ab Kinazolinski derivati
US20060264493A1 (en) 2003-02-17 2006-11-23 Ermes Vanotti Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
GB0315657D0 (en) 2003-07-03 2003-08-13 Astex Technology Ltd Pharmaceutical compounds
US7141568B2 (en) 2003-07-09 2006-11-28 Pfizer Italia S.R.L. Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US20050025605A1 (en) * 2003-07-30 2005-02-03 Vrana John J. Locator stud and method of assembly
EP1663242B1 (en) 2003-08-07 2011-04-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ES2540987T3 (es) * 2004-05-14 2015-07-15 Millennium Pharmaceuticals, Inc. Métodos para preparar inhibidores de la aurora cinasa
JP4812763B2 (ja) 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ， インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
EP1781653A1 (en) 2004-07-05 2007-05-09 Astex Therapeutics Limited 3,4-disubstituted pyrazoles as cyclin dependent kinases (cdk) or aurora kinase or glycogen synthase 3 (gsk-3) inhibitors
US7601725B2 (en) 2004-07-16 2009-10-13 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as Aurora kinase inhibitors
GB2420559B (en) 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
ATE421996T1 (de) 2004-11-15 2009-02-15 Rigel Pharmaceuticals Inc Verfahren zur herstellung optisch aktiver n- carbamat-geschützter beta-lactame durch optische auflösung unter verwendung einer candida antarctica lipase
US8153630B2 (en) 2004-11-17 2012-04-10 Miikana Therapeutics, Inc. Kinase inhibitors
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
EP1836199A1 (en) 2004-12-30 2007-09-26 Astex Therapeutics Limited Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases
BRPI0519759A2 (pt) 2004-12-30 2009-03-10 Astex Therapeutics Ltd composiÇÕes farmacÊuticas
WO2006070202A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives having kinase modulating activity
US7485661B2 (en) 2005-01-18 2009-02-03 Pfizer Italia S.R.L. Heterobicyclic pyrazole derivatives as kinase inhibitors
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
ES2535854T3 (es) 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Compuestos de pirazol sustituidos
SG166827A1 (en) 2005-11-03 2010-12-29 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
DK1962830T3 (da) * 2005-12-23 2013-06-24 Glaxosmithkline Llc Azaindolhæmmere af aurorakinaser.
CN100346830C (zh) * 2005-12-28 2007-11-07 上海交通大学医学院附属瑞金医院 一种治疗b细胞淋巴瘤的药物组合物
EP2295432A1 (en) * 2006-02-10 2011-03-16 TransTech Pharma Inc. Process for the preparation of aminobenzimidazole derivatives
TW200808311A (en) 2006-03-30 2008-02-16 Nerviano Medical Sciences Srl Use of a kinase inhibitor for the treatment of particular resistant tumors
WO2007132221A1 (en) 2006-05-12 2007-11-22 Cyclacel Limited Combined anticancer pyrimidine-thiazole aurora kinase inhibitors
GB0609530D0 (en) 2006-05-12 2006-06-21 Cyclacel Ltd Combination
WO2007132220A1 (en) 2006-05-12 2007-11-22 Cyclacel Limited Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder
WO2008005266A2 (en) * 2006-06-30 2008-01-10 Schering Corporation Method of using substituted piperidines that increase p53 activity
WO2008021038A2 (en) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) * 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090023743A1 (en) * 2007-05-09 2009-01-22 Abbott Laboratories Inhibitors of protein kinases
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
MX2011006725A (es) 2008-12-22 2011-09-15 Millennium Pharm Inc Combinacion de inhibidores de aurora cinasa y anticuerpos anti-cd20.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
EP2496604B1 (en) * 2009-11-06 2017-08-23 IDEXX Laboratories, Inc. Canine anti-cd20 antibodies
RU2012140021A (ru) * 2010-02-19 2014-03-27 Миллениум Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ

Also Published As

Publication number Publication date
RU2535032C2 (ru) 2014-12-10
EP2376082B1 (en) 2014-03-05
KR101741168B1 (ko) 2017-05-29
WO2010074724A1 (en) 2010-07-01
CN102264368B (zh) 2014-09-10
CA2747326C (en) 2017-05-16
BRPI0923579A2 (pt) 2020-01-14
JP5738196B2 (ja) 2015-06-17
JP2012513390A (ja) 2012-06-14
AU2009330727B2 (en) 2016-07-28
ES2468391T3 (es) 2014-06-16
KR20110114586A (ko) 2011-10-19
CN102264368A (zh) 2011-11-30
US20160271249A1 (en) 2016-09-22
AU2009330727A1 (en) 2011-07-07
US10391100B2 (en) 2019-08-27
EP2376082A1 (en) 2011-10-19
RU2011130566A (ru) 2013-01-27
US20170296551A1 (en) 2017-10-19
US20100183601A1 (en) 2010-07-22
MX2011006725A (es) 2011-09-15
CA2747326A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
HK1160766A1 (en) Combination of aurora kinase inhibitors and anti-cd20 antibodies cd20
HUS2100008I1 (hu) Halauxifen-metil és floraszulam kombinációja
IL248723B (en) Specific antibodies against the bcr complex and methods of using them
IL198020A0 (en) Anti-cd20 antibodies and methods of use
HK1160119A1 (en) Kinase inhibitors and methods of use
EP2252293A4 (en) KINASEHEMMER AND USE PROCESS
IL216511A0 (en) Janus kinase inhibitor compounds and methods
HK1144306A1 (zh) 激酶抑制劑及其用途
IL211549A0 (en) Aminotriazolopyridines and their use as kinase inhibitors
HK1172896A1 (zh) 化合物和使用方法
HK1161094A1 (en) Compounds and methods of use
ZA200906946B (en) Inhibitors of iap
EP2121637A4 (en) ANTHRANILAMIDE INHIBITORS OF AURORA KINASE
PL2373691T3 (pl) PRZECIWCIAŁA ANTY-fXI I SPOSOBY ZASTOSOWANIA
EP2387572A4 (en) PROTEIN KINASE C HEMMER AND ITS USE
IL211623A0 (en) Anti-notch2 antibodies and methods of use
EP2365809A4 (en) PYRAZINOPYRZINE AND DERIVATIVES AS KINASEHEMMER
IL207415A0 (en) Protein kinase inhibitors and use thereof
EP2242854A4 (en) COMPOUNDS AND USES THEREOF
DK2358710T3 (da) AKT- og P70-S6-kinaseinhibitorer
ZA201003420B (en) Protein kinase inhibitors and use thereof
ZA201106697B (en) Humanized anti-cd20 antibodies and methods of use
EP2379076A4 (en) PHOSPHODIESTERASE HEMMER AND ITS USES
GB0805693D0 (en) Combinations of P13-delta and P13-gamma kinase inhibitor compounds
IL211752A0 (en) Antibody combinations and use of same for treating cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211212